Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

651
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
651
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

652
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship Between Cerebral Oximetry and Outcomes in Post-Cardiac Arrest Patients: A Systematic Review and Meta-Analysis.

Critical care explorations·2026
Same author

Prevalence, semiology and neuroimaging of movements in comatose adults at risk of death by neurologic criteria: a prospective cohort study.

Critical care (London, England)·2026
Same author

Clinical and Demographic Predictors of Optic Neuritis Subtype.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Artificial Intelligence-Based Prognostic Models for Postoperative Outcomes in Vitreoretinal Surgery: A Systematic Review and Meta-Analysis.

Ophthalmology. Retina·2026
Same author

What a mesh: a call for better science and regulatory oversight.

The British journal of surgery·2026
Same author

Synthetic cervical spine radiographs: expert validation and transfer learning for low-data settings.

BMC medical informatics and decision making·2026

Related Experiment Video

Updated: Feb 26, 2026

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
08:38

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge

Published on: April 9, 2012

21.1K

Refractory Longitudinally Extensive Transverse Myelitis Responsive to Cyclophosphamide.

Laura J Baxter1, Shuo Chen1, Philippe Couillard1

  • 11Department of Clinical Neurosciences, Faculty of Medicine,University of Calgary,Calgary,Alberta.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|July 21, 2017
PubMed
Summary

Severe longitudinally extensive transverse myelitis (LETM) is a debilitating condition. Cyclophosphamide induction offers a promising treatment option for severe cases unresponsive to standard therapies, leading to significant patient recovery.

Area of Science:

  • Neuroimmunology
  • Neurology
  • Clinical Medicine
Keywords:
cyclophosphamideneuroimmunologytransverse myelitis

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Related Experiment Videos

Last Updated: Feb 26, 2026

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
08:38

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge

Published on: April 9, 2012

21.1K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Background:

  • Severe longitudinally extensive transverse myelitis (LETM) can result in profound neurological deficits, including quadriplegia and respiratory failure.
  • Conventional immune therapies, such as corticosteroids, plasma exchange, intravenous immunoglobulin, and rituximab, are not always effective in treating LETM.
  • Refractory cases of LETM pose a significant clinical challenge, necessitating exploration of alternative treatment strategies.